Search the Newsreel

Neurocrine Biosciences Releases Q2 2026 Financial Results

Neurocrine Biosciences reported strong Q2 2026 financial results, with non-GAAP earnings per share of $2.85, significantly beating analyst expectations, and revenue reaching $959.0M, an 8.0% increase over forecasts. The company's flagship product, INGREZZA, contributed $716.0M to revenue, and full-year revenue guidance was set between …

Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates

Neurocrine Biosciences (NBIX) exceeded Q2 earnings and revenue estimates, reporting $2.85 per share against an expected $2.26, and revenues of $959 million, beating the $901.6 million consensus. The company has a strong track record of surpassing estimates and its shares have gained 27.5% year-to-date, …

Neurocrine Biosciences Q2 revenue rises 39% to $959 million

Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q2 Adjusted EPS $2.85 per Share, vs. FactSet Est of $1.66

Neurocrine Biosciences Inc. (NBIX) reported Q2 adjusted earnings per share of $2.85, significantly surpassing the FactSet estimate of $1.66. The company also announced Q2 revenue of $959.0 million, exceeding the FactSet estimate of $891.2 million. The article highlights recent news related to Neurocrine Biosciences, …

Biotech Stocks At 52-Week Highs - ANIK & CHE Rise With Q2 Results, ICUI, NBIX, RPRX

Several biotech stocks, including Anika Therapeutics (ANIK), Chemed Corporation (CHE), ICU Medical (ICUI), Neurocrine Biosciences (NBIX), and Royalty Pharma (RPRX), reached new 52-week highs on July 29, 2026. This surge was primarily driven by strong second-quarter financial results and ongoing positive clinical research updates …

Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis

Neurocrine Biosciences Inc (NBIX) currently holds a financial score of 8.50, placing it 50th out of 155 companies in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 42.25% to $814.50 million and …

Neurocrine Biosciences, Inc. Revenue Breakdown – BX:NB3

Neurocrine Biosciences, Inc. (BX:NB3) reported a total revenue of 2.27 billion CHF last year, primarily driven by its Pharmaceuticals segment. The majority of this revenue, also 2.27 billion CHF, came from operations within the United States. This indicates a strong reliance on the pharmaceutical …

Neurocrine Biosciences stock hits all-time high at 181.3 USD

Neurocrine Biosciences Inc. (NBIX) reached an all-time stock high of $181.30, reflecting a 34.56% increase over the past year. Analysts have revised earnings estimates upward, and the stock trades at a PEG ratio of 0.22, suggesting it remains undervalued according to InvestingPro analysis despite …

Neurocrine’s 33% quarter outruns weak drugmaker breadth, but average volume keeps the move under review

NBIX closed at $175.8, just 3.0% below its 52-week high, with an active weekly Trend Signal and positive Market Dynamics. The reservation is participation, with latest volume at only 1.0x the 13-week average.

Net margin % of Neurocrine Biosciences, Inc. – HAM:NB3

This page from TradingView provides financial information for Neurocrine Biosciences, Inc. (HAM:NB3), specifically focusing on its net margin percentage. It details market performance on the Hamburg Stock Exchange and offers tools for financial analysis. The content primarily lists product offerings and company information related …

Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?

Neurocrine Biosciences (NBIX) is slated to report its second-quarter 2026 earnings on July 30, with investors keenly focused on the sales performance of its key products, Ingrezza and Crenessity, and updates on its neuroscience pipeline. The Zacks Consensus Estimate projects revenues of $901.54 million …

JPMorgan discloses 6.3% Neurocrine stake in 13G/A filing (NBIX)

JPMorgan Chase & Co. has filed an amended Schedule 13G/A, reporting a beneficial ownership of 6.3% in Neurocrine Biosciences, Inc. common stock, totaling 6,338,240 shares. The filing details JPMorgan's sole voting power over 5,719,691 shares and sole dispositive power over 6,337,388 shares. This disclosure …

Weekly Recap: Guggenheim hikes NBIX price target and Siddhanti named CBO

Guggenheim has reiterated a Buy rating on Neurocrine Biosciences (NBIX) and increased its price target to $200. Additionally, Neurocrine Biosciences has appointed Samir Siddhanti as its new Chief Business Officer, tasked with driving growth, business development, and corporate strategy, aiming to maximize the value …

Neurocrine Biosciences (NBIX) Refreshes Leadership On A Narrative That Still Sees Undervaluation

Neurocrine Biosciences (NBIX) has appointed new leadership, including a Chief Business Officer and three Senior Vice Presidents, amidst a rising stock price with a 90-day return of 37.28% and a one-year return of 33.02%. The company is considered undervalued with a fair value of …

How Investors Are Reacting To Neurocrine Biosciences (NBIX) Leadership Hires In Business And Market Access

Neurocrine Biosciences recently appointed Samir Siddhanti as Chief Business Officer and several Senior VPs, aiming to strengthen commercial execution and broaden its biopharma portfolio. While these hires are seen as positive for the company's long-term strategy, particularly in business development and market access for …

Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Neurocrine Biosciences Inc (NBIX), identifying its major institutional holders and their respective proportions. It also outlines the types of shareholders, the historical institutional shareholding, and recent shareholder activities. Additionally, it lists several ETFs that include NBIX in …

Neurocrine Hires Market Access Chief, Promotes Two Executives

Neurocrine Biosciences has appointed three new Senior Vice Presidents to strengthen its leadership team, focusing on expanding its commercial portfolio and advancing its neuroscience pipeline. Bret Paulson joins as SVP, Market Access, while David Bradfute is promoted to SVP and Global Head of Intellectual …

Neurocrine Biosciences names three senior vice presidents By Investing.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has appointed three new senior vice presidents to its leadership team: Bret Paulson as Senior Vice President of Market Access, David Bradfute as Senior Vice President and Global Head of Intellectual Property, and Aaron Vosburgh as Senior Vice President of …

Neurocrine Biosciences (NBIX) Stock Trades Fair On Earnings But Mixed On Value

Neurocrine Biosciences (NBIX) stock has seen significant returns over the past five years, suggesting that current valuations might make it a hold rather than a clear bargain. The company's P/E ratio is fair compared to the biotech industry, and narratives vary from an underappreciated …

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

Neurocrine Biosciences has announced key leadership appointments and promotions to strengthen its team during a new phase of growth. Bret Paulson joins as Senior Vice President, Market Access, while David Bradfute is promoted to Senior Vice President and Global Head of Intellectual Property, and …

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NBIX: Neurocrine Biosciences, Inc. Latest Stock Price, Analysis, News and Trading Ideas

This article provides details on Neurocrine Biosciences, Inc. (NBIX), including its latest stock price, key financial metrics like market cap and P/E ratio, and upcoming earnings date. It also links to recent news releases concerning the company's leadership changes and displays trending stock discussions.

Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti To Lead Growth After $2.9 Billion Deal

Neurocrine Biosciences (NBIX) has appointed Samir Siddhanti as Chief Business Officer to lead business development, corporate strategy, and alliance management. This appointment follows the company's recent US$2.9 billion acquisition of Soleno Therapeutics and aims to formalize leadership for deal-making, pipeline shaping, and long-term growth. …

Neurocrine Biosciences names Siddhanti chief business officer

Neurocrine Biosciences has appointed Samir Siddhanti as its new Chief Business Officer, where he will oversee business development, corporate strategy, alliance management, and program management. Siddhanti, who joined the company in 2017 and previously served as Vice President of Business Development, was instrumental in …

Neurocrine Biosciences (NBIX) Stock Looks Reasonable At Today’s Price

Neurocrine Biosciences (NBIX) stock is currently considered roughly fairly valued based on market multiples and a tailored P/E benchmark. While the company has shown strong returns over five years, its P/E ratio is above the biotech industry average. The article presents both bull and …

Is Neurocrine Biosciences (NBIX) Still Undervalued Or Does Its P E Leave Little Upside?

Neurocrine Biosciences (NBIX) stock has seen mixed short-term moves but strong long-term returns. Despite a narrative suggesting it's 11.4% undervalued with a fair value of $192.88 based on future growth and an extensive pipeline, its P/E ratio of 25.7x is higher than industry averages, …

Price to sales forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX

The article focuses on the "Price to sales forward" metric for Neurocrine Biosciences, Inc. (NASDAQ: NBIX) as displayed on TradingView. It provides financial data and an overview of the company's market performance. The content appears to be a stub or a section from a …

NEUROCRINE BIOSCIENCES, INC. : WELLS FARGO RAISES TARGET PRICE TO $200 FROM $175

Wells Fargo has increased its target price for Neurocrine Biosciences, Inc. (NBIX.O) from $175 to $200. This update from Reuters indicates a positive outlook from the financial institution regarding the pharmaceutical company's valuation. The article briefly notes the published time from Reuters as 2026/07/17 …

Should Strong Earnings Projections and Zacks Rank #1 Status Require Action From Neurocrine Biosciences (NBIX) Investors?

Neurocrine Biosciences (NBIX) is projected to achieve 48.4% earnings growth this year and holds a Zacks Rank #1 (Strong Buy), indicating positive analyst sentiment. The article discusses how this strong outlook reinforces confidence in the company's focus on neurological and psychiatric disorders, specifically the …

BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $199

BofA Securities has reiterated its Buy rating on Neurocrine Biosciences (NBIX.US) and set a price target of $199. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.

Neurocrine’s 28% quarter reaches the range top with only 1.1x volume

NBIX closed within 0.6% of its 52-week high after a 6.5% week, but participation was only modest and the Sharemaestro read remains balanced rather than decisive.